ARTICLE
2022 Best Lawyers Business Edition | The Litigation Issue
Summer 2022
Read time: 2 min
Ted M. Becker and John J. Song authored the article COVID-19 and a Cloud of Dust, featured in 2022 Best Lawyers Business Edition – The Litigation Issue.

ARTICLE
Summer 2022
Read time: 2 min
Ted M. Becker and John J. Song authored the article COVID-19 and a Cloud of Dust, featured in 2022 Best Lawyers Business Edition – The Litigation Issue.

ARTICLE / CLIENT ALERT
August 1, 2022
Read time: 9 min
The Economic Crime (Transparency and Enforcement) Act 2022 (the Act), enacted in March 2022, introduced a Register of Overseas Entities. Under this legislation, overseas entities which own certain interests in United Kingdom (UK) land will be required to collect, verify and register information about the ultimate beneficial owners of the entities. Some, but not all, of this information will be publicly inspectable and there will be sanctions for failure to comply. More information on the register is set out below. The transitional period for compliance with the new registration requirement for entities already owning UK land starts on 1 August 2022 and will close on 31 January 2023. As the information gathering and verification exercise may take some time, it is recommended to act now.
Overview
The Act places an obligation on entities that are established under a law of a jurisdiction outside the UK to register prescribed information with the registrar of companies. For the obligation to be triggered the non-UK entity must own or wish to be registered as the owner of certain interests in UK land. In order to be registered, the non-UK entity must provide, amongst other information, details of individuals who are identified as their ultimate beneficial owner for the purposes of the Act (registrable UBO). The core implications are as follows:
Who Is Affected?
This regime is aimed at entities established under the laws of a jurisdiction outside the United Kingdom which, under those same laws, have separate legal personalities. This could be a limited company, a body corporate, certain types of partnership, civil law foundations, etc. The definition of a legal entity would cover most common corporate ownership situations, such as Channel Island holding companies or United States (US) limited liability companies. There are provisions in the Act to exempt certain non-UK entities from these obligations, but these are narrow and unlikely to be practically relevant to most holding structures.
Companies and partnerships established under the laws of a UK jurisdiction are not covered. However, it is likely such UK entities will already have had to disclose their ultimate beneficial owners under the current PSC regime. It should be noted that non-UK corporate trust companies will be expected to register where they own an interest in UK land; in some cases, the trust may also be registrable under the Trust Registration Service.
What Interests in UK Land Trigger the Obligation?
From an English perspective, any freehold or leasehold (granted for a term of more than seven years) interest in UK land—whether residential or otherwise—will trigger the obligation. Furthermore, where the interest was already owned on 28 February 2022, there will be an obligation to comply with the Act’s requirements if the interest in land is in land in England or Wales and the land was acquired on or after 1 January 1999. This is the case even if the land has been disposed of after 28 February 2022.
Due to the separate legal systems, the definition of relevant interest in land is different for Scotland and Northern Ireland.
What Will Change?
Rather than simply registering the non-UK entity’s legal ownership with the relevant UK land registry (England and Wales and Scotland have separate registration regimes already), the non-UK entity will need to register with the companies registrar and be issued with a registration number to allow it to become a registered owner of UK land before seeking to register their title with the relevant land registry. To obtain that registration number, the non-UK entity will need to have undertaken the required due diligence process to identify any relevant owners and controllers, the registrable UBOs, and collect the registrable information on each. It should be noted that a registrable UBO of the non-UK entity is not necessarily the same thing as the owner/controller of the UK land which triggers the registration obligation.
Entities that currently hold UK property will be granted a six-month transition period, starting 1 August (giving until 31 January 2023 to register).
What Needs to Be Registered?
The non-UK entity will need to register specific details about itself, but the centre of the proposed regime is the non-UK entity’s owner/controller register, based on and closely resembling the existing PSC registration regime.
The initial obligation of the non-UK entity is to take steps to identify the existence and identity of registrable UBOs. These can include serving information request notices on known or suspected UBOs and undertaking information verification obligations before the information is verified by a relevant person (which includes an independent legal professional) before being registered with Companies House.
Were an individual registrable UBO is identified, the information which must be registered will include:
In relation to the final item of information, the Act adopts a broadly similar definition for registrable ownership and/or control as the one used for the PSC regime. Therefore, any individual who meets one or more of the following criteria will be considered a reportable person for the purposes of the new register:
If the owner happens to be another entity, the non-UK entity will be required to take steps to identify and disclose the ownership and control further up the ownership chain until either a relevant individual is identified, or it is clear there is no such controller. In the latter case, the non-UK entity’s managing officers must be registered.
There are provisions for individuals who hold rights or shares collectively so that their beneficial ownership cannot go unreported as a result of dilution of their shareholding (or equivalent).
Finally, it should be noted that the Act contemplates that regulations can be introduced to prevent registered information from being made public in certain circumstances. Currently, an application can be made to protect certain information on the grounds that there is a reasonable belief that by making the information available, the activities of the overseas entity or one or more characteristic or personal attributes of the relevant individual when associated with that overseas entity, will put the relevant individual or a person living with them at serious risk of being subject to violence or intimidation. This is likely to protect information only in very limited circumstances.
What if a Registrable UBO Is a Trustee?
The Act brings in new obligations on trustee UBOs to disclose information on the trust. Whilst this trust information will not be available for public inspection (unless it is already in the public realm), it is a significant additional disclosure obligation as the information can be shared by Companies House with HMRC and any other public persons which are specified in regulations in the future.
The registrable trust information includes the name and date of the trust and information on all beneficiaries of, settlors of, and holders of certain powers over the trust, whether or not they are registrable UBOs. In the latter case (certain powers holders), the relevant powers are those which enable the holder to remove and appoint trustees and any power which is a right held “in respect of the exercise by the trustees of their functions”, such as consent powers.
What Are the Sanctions for Failure to Comply?
Serious practical repercussions could stem from failure to register beneficial ownership. Without the aforementioned registration number, the entity will not be able to register the acquisition of property at the relevant land registry. Inability to register as the owner of the land will make it nearly impossible to effectively sell, grant security over (including by mortgaging), lease, or otherwise make any dispositions regarding the land. This is likely to complicate land purchases in the future unless these obligations are considered early in the process.
Furthermore, failing to comply with registration requirements, failing to update information, or supplying false or misleading information will be criminal offences committed by the non-UK entity and/or the entity’s officers. People served with formal information requests and who fail to comply with them will also commit an offence.
What Actions Should You be Taking?
All non-UK entities and structures owning UK land, need to undertake a review to determine whether they are caught by the Act and, if so, to undertake the required UBO identification steps discussed above. This may be a relatively straightforward exercise for corporate holding structures, but is likely to be more complex for structures which are held in trusts and may require specialist advice. In any event, the information will need to be verified by an appropriate professional before it can be registered, and all this is likely to require action well in advance of the expected deadline of 31 January 2023. If we can provide assistance, please reach out to your existing McDermott contact or directly to Simon Gibb and Simon Goldring.

ARTICLE / CLIENT ALERT
July 29, 2022
Read time: 9 min
On July 27, 2022, Senate Majority Leader Chuck Schumer (D-NY) and Senator Joe Manchin (D-WV) announced an agreement on a climate, health and tax reconciliation package dubbed the Inflation Reduction Act of 2022 (IRA). The IRA, if enacted in its current form, would further limit long-term capital gain eligibility for carried interest by, among other things, increasing the required holding period from three to five years. The IRA also proposes changes to the carried interest rules that are identical to changes that were proposed in September 2021 in the House Ways & Means (W&M) Committee reconciliation bill as part of the Build Back Better Act reconciliation legislation (W&M Proposal). This article summarizes certain key changes to the carried interest rules in the IRA which, if enacted in its current form, would increase the tax burden on investment professionals and other taxpayers under certain circumstances.
OVERVIEW OF CARRIED INTEREST RULES
Section 1061 of the Code, enacted in 2017 as part of the Tax Cuts and Jobs Act, recharacterizes certain gain that would otherwise qualify as long-term capital gain with respect to “applicable partnership interests” as short-term capital gain.[1] An applicable partnership interest is any interest in a partnership which, directly or indirectly, is transferred to (or is held by) a taxpayer (a Carried Interest Holder) in connection with the performance of substantial services by that taxpayer, or any other related person, in any applicable trade or business (Carried Interest). Thus, under Section 1061, a three-year holding period generally is required for a holder of a Carried Interest to qualify for long-term capital gains treatment with respect to that interest.
IS THE HOLDING PERIOD REALLY FIVE YEARS?
Like the W&M Proposal, the IRA would extend the current three-year holding period to five years for investment fund managers (and certain other taxpayers) to qualify for long-term capital gain with respect to their Carried Interests. Any other gain would be treated as short-term capital gain (generally taxed at ordinary income rates).
The five-year holding period generally would begin on the later of:
Neither the IRA nor the existing statute defines “substantially all.” While previous proposed regulations defined “substantially all” of an investment fund’s assets to mean 80% of such assets (excluding cash and certain other assets), such definition was not adopted in the final regulations. Moreover, under the IRA, a validly made election under Section 83(b) upon receipt of unvested Carried Interest will not cause the applicable Carried Interest Holder to be treated as acquiring substantially all of its Carried Interest. In order to avoid a delay in the five-year holding period beginning under the test set forth above, investment professionals may need to tweak their approach to time and performance vesting in current arrangements.
Treasury Regulations will be needed to provide certainty for investment professionals as they apply the “substantially all” test across an investment portfolio that will undoubtedly include various special purpose vehicles and parallel funds.
Similar rules apply to tiered partnerships where the upper-tier partnership receives Carried Interest in a lower-tier partnership. However, it is unclear the extent to which Carried Interest in a lower-tier partnership that does not meet the foregoing holding period requirements may impact the taxability of gain on Carried Interest in an upper-tier partnership that is not otherwise attributable to such lower-tier Carried Interest.
Notwithstanding the limitations described above, for (1) taxpayers (other than trusts or estates) with adjusted gross income of less than $400,000 or (2) any income that is attributable to a real property trade or business, only a three-year holding period (subject to the same later of determination discussed above) is required.
This is a significant unfavorable change to investment professionals. In addition to the uncertainty of when an investment fund is treated as acquiring “substantially all” of its investments, in practice, given that investment funds typically deploy capital over a multiyear investment period, such funds may not be considered to have invested “substantially all” of their assets for several years, thereby delaying the start of the holding period requirement. This delay could extend the holding period requirement well beyond the headline five-year holding period requirement (and possibly even beyond the ownership of an investment). For example, if a private equity fund is only considered to have acquired “substantially all” of its assets in year four of the fund’s life, the holding period with respect to Carried Interest held by an investment fund manager would only begin in year four and would effectively be extended to nine years.
EXPANDED SCOPE OF CHARACTER RECLASSIFICATION
As was the case with the W&M Proposal, the carried interest provisions in the IRA appear intended to materially expand the scope of the current gain recharacterization rules under Section 1061. The “net applicable partnership gain” of a Carried Interest Holder that is subject to recharacterization (absent the availability of an applicable exception) would not only cover gains and losses realized by such Carried Interest Holder with respect to its Carried Interest directly (e.g., on a sale or exchange of that Carried Interest), but would be expanded to capture other items of income allocable to a Carried Interest Holder from items that—but for special characterization rules—would not otherwise be classified as long-term capital gains. For example, Section 1231 provides that gain recognized upon a sale or exchange of property used in a trade or business is (subject to certain exceptions) treated as long-term capital gains. Such Section 1231 gain is also currently treated as long-term capital gain for purposes of Section 1061. The IRA would revise Section 1061 to negate that long-term capital gain characterization for a Carried Interest Holder’s allocable share of such gain. This would have the effect of eliminating one planning alternative whereby a partnership sells its assets used in a trade or business as opposed to the partners (including a Carried Interest Holder) selling their interests in the partnership. Under the revised rules, the portion of such long-term capital gain allocable to a Carried Interest Holder would, absent an applicable exception, be treated as ordinary income instead. This change would appear to impact several other similar preferential “character” rules in other contexts, including qualified dividend income received by a partnership in which a partner holds Carried Interest.
ALL IN THE FAMILY
Under the existing regime, if a taxpayer transfers Carried Interest (directly or indirectly) to a related person, the taxpayer must include gross income (as short-term capital gain) and the excess of the long-term gain with respect to such Carried Interest that is attributable to the sale or exchange of an asset held for three or fewer years and that is not otherwise treated as short-term capital gain under the carried interest rules with respect to the transfer of the Carried Interest. While the existing regulations clarify that this rule does not result in the acceleration of gain with respect to all transfers of Carried Interest to a related party, the IRA would drastically alter these rules by requiring full gain recognition on any transfer of Carried Interest to a related party. This revised rule would effectively disregard the nonrecognition rules otherwise applicable to transfers of this kind.
For this purpose, a related person includes:
If enacted, the limitation on transfers to related parties resulting from the IRA is likely to have far-reaching impacts on estate planning considerations for taxpayers holding a Carried Interest.
FAMILY OFFICES STILL WAITING FOR GUIDANCE
The IRA carried interest rules would retain the broad provision that says the Secretary of the Treasury (in regulations) can provide that the recharacterization rules of Section 1061 do not apply to income or gain attributable to any asset not held for portfolio investment on behalf of third-party investors. Since the original Section 1061 rules were adopted in 2017, this has been commonly considered by practitioners as a potential exception for family offices since holders of Carried Interests in such contexts arguably are not overseeing portfolio investments of third-party investors, but rather just family members. To date, no regulations have been issued and the IRA proposal retains the language without any further clarification on its scope or intent.
NEXT UP: WAIVER ARRANGEMENTS?
Some investment funds also utilize carried interest waivers, pursuant to which the Carried Interest Holder may waive its entitlement to gain from the sale of assets that would be classified as short-term capital gain under Section 1061 in exchange for an additional allocation of future gain from the sale of other assets. Another arrangement of investment fund managers that the IRS has been evaluating since 2015 (when proposed regulations were issued) is the use of preferential “fee waivers,” whereby a fund manager may waive its entitlement to management fees (which are generally taxed as ordinary income) in exchange for additional Carried Interest (potentially eligible for preferential long-term capital gains treatment). The 2015 proposed regulations set forth guidelines as to when such arrangements potentially would not be respected yet have not been adopted to date. Along with the other changes to Section 1061, the IRA proposal includes authority for the US Department of the Treasury to develop regulations that “prevent avoidance” of the Section 1061 rules, including through the use of “carry waivers.” It appears that US Congress may be looking to revisit carry waivers and use compliance with Section 1061 to potentially further restrict such arrangements. Any validly waived management fees would appear to continue to qualify as Carried Interest, however, such Carried Interest attributable to waived fees would be subject to the modified Section 1061 rules. We’ll continue to scrutinize the viability and efficiency of waiver arrangements for our clients.
EFFECTIVE DATE
If the IRA is passed as currently proposed, the new carried interest rules discussed above would become effective for tax years beginning after December 31, 2022. Among other planning matters to be considered and reevaluated in the interim, Carried Interest Holders contemplating any estate planning transfers of their Carried Interests, in particular, should consider whether time is now of the essence to do so before year-end.

ARTICLE / CLIENT ALERT
July 29, 2022
Read time: 7 min
On July 27, 2022, Senator Joe Manchin (D-WV) and Senate Majority Leader Chuck Schumer (D-NY) announced that they had reached an agreement on a proposed reconciliation package: the Inflation Reduction Act of 2022, HR 5376, 117th Cong. (Act). The Act includes $369 billion in energy and climate spending and contains several new or expanded sources of government support for the development of a domestic clean energy industry and for the gradual transition to a more sustainable energy economy.
Major provisions of the Act that are of most interest to the clean energy industry include (1) extension and expansion of existing investment and production tax credits for renewable energy; (2) a mechanism to sell tax credits for renewable energy; (3) tax credits for the domestic production of solar cells; (4) manufacturing tax credits for energy storage systems; (5) investment tax credits for industrial or manufacturing facilities for the production of green energy merchandise; (6) additional funding for US Department of Energy (DOE) loans; (7) a 10-year extension of tax credits for rooftop solar panels; and (8) a program for energy-efficient affordable housing.
Importantly, the Act contains an additional $500 million appropriation to carry out the Defense Production Act (DPA). The Act does not contain, nor have we seen elsewhere, any additional information on the specifics of how the Biden administration intends to use these appropriated funds. The administration has previously announced its intention to use the DPA to accelerate the domestic production of solar cells and related materials.
A DEEPER DIVE
Getting a bit more granular on each of the above:
1. Renewable Energy Tax Credits: The Act incorporates many of the original features we saw in last year’s Build Back Better Act proposals:
2. Tax Credits for the Domestic Production of Solar Cells, Modules and Components: The Act includes most of the operative provisions of the proposed Solar Energy Manufacturing for America Act, in particular, tax credits for the domestic production of solar cells, modules and components thereof. The specific credits are:
3. Manufacturing Tax Credits: The Act would expand advanced manufacturing tax credits to cover up to a 30% credit for energy storage systems.[2]
4. Tax Credits for Industrial or Manufacturing Facilities: The Act has $10 billion in investment tax credits for industrial or manufacturing facilities to produce green-energy merchandise, including solar cells and related components, wind turbine components, electric and hybrid vehicles and renewable fuel production equipment.[3]
5. DOE Loans: The DOE will receive an additional $40 billion for loans under section 1703 of the Energy Policy Act of 2005 and $5 billion for activities under section 1706 of that act.[4]
6. Residential: Several other provisions of the Act should also increase domestic demand for solar panels and related equipment, including:
7. DPA: The Biden administration has previously announced its intention to use the DPA to accelerate the domestic production of solar cells and related materials.[7] The Act contains an additional $500 million appropriation to carry out the DPA.[8] However, the Act does not specify (nor has other information been released about) how the administration intends to use these appropriated funds.
We’ve noted that the Act has not yet received the public support of all other Democratic senators, nor has it passed the Senate Parliamentarian’s review for reconciliation purposes (referred to as a “Byrd Bath”), both of which will be required before the Act can be passed—assuming no Republican senators support the bill. As such, much of the above is subject to amendment and could be removed if found to be outside of the scope of reconciliation by the Senate Parliamentarian.
McDermott’s tax, transactional, policy and trade teams are continuing to monitor the legislative process as the Act moves forward and will provide updates as they are made known.

ARTICLE / CLIENT ALERT
July 28, 2022
Read time: 5 min
As of July 26, 2022, there are 3,591 confirmed cases of monkeypox in the United States, according to US Centers for Disease Control and Prevention (CDC) data, and the World Health Organization (WHO) Director-General has declared the multi-country monkeypox outbreak a Public Health Emergency of International Concern (PHEIC). With much about the potential impact and scope of monkeypox still unknown, employers should consider taking proactive steps now, as may be appropriate for their workforce, to enhance and reinforce the safety protocols already in place from the COVID-19 pandemic. This On the Subject covers three key considerations for employers with respect to monkeypox.
1. EDUCATE THE WORKFORCE REGARDING MONKEYPOX.
Employers should consider updating their current pandemic safety policies to include information about monkeypox, including how the virus is spread and its symptoms.
How monkeypox spreads. According to the WHO, the monkeypox virus is transmitted through close contact with another infected person, contaminated materials or an infected animal. With respect to person-to-person spread, the virus can spread face-to-face, skin-to-skin, mouth-to-mouth or mouth-to-skin, though possible transmission through the air is not yet well understood. As for animals, monkeypox can spread to people when they come into physical contact with an infected animal, especially those that are sick or dead.
Monkeypox symptoms. Symptoms of monkeypox infection include some or all of the following:
The incubation period (which is the interval from infection to onset of symptoms) for monkeypox can last up to 21 days. In contrast to COVID-19, it is not yet clear whether people with monkeypox who are asymptomatic can spread the disease. If an employee tests positive for monkeypox, the illness can generally last between two to four weeks.
2. IMPLEMENT A POLICY REGARDING EMPLOYEE MONKEYPOX EXPOSURE AND DIAGNOSIS.
Just as with COVID-19, if an employee has monkeypox, they should not come to the worksite. Moreover, if an employee has had close contact with someone who has been diagnosed with monkeypox or exposed to an environment contaminated with the virus, they should monitor themselves closely for monkeypox symptoms for the 21-day incubation period.
Many employers have already implemented COVID-19 self-monitoring requirements for employees. These measures require employees to assess whether they exhibit any symptoms of the virus and, if so, not to report to work. Employers may consider updating their self-monitoring policies to expand symptoms to include all monkeypox symptoms, too. Any employee who exhibits monkeypox symptoms should contact their healthcare provider for medical advice, testing and care.
While there are no laws that currently require employers to provide paid leave for monkeypox specifically, there are several states and local jurisdictions with paid sick leave requirements; these laws may cover certain absences related to monkeypox. Employers should consult with employment counsel to determine the applicability of such laws to monkeypox infection and exposure.
3. EXPAND EXISTING COVID-19 PROTOCOLS TO ADDRESS THE PREVENTION OF MONKEYPOX IN THE WORKPLACE.
Employers will find that, in many ways, monkeypox spread and symptom information overlaps with COVID-19 information. Likewise, the recommended preventative measures from the CDC and WHO mirror COVID-19 prevention in many ways. Therefore, employers may find it most efficient to review and update their existing COVID-19 safety protocols to reflect a more expansive safety protocol applicable to monkeypox.
Employers can share the following information about ways to prevent monkeypox spread, per the WHO and CDC:
THE MCDERMOTT DIFFERENCE
For more information and assistance with employment policies regarding monkeypox, please feel free to contact our employment team, who can help you prepare or update your safety policy to meet your business’s needs.

ARTICLE / CLIENT ALERT
July 28, 2022
Read time: 10 min
On July 20, 2022, the US Department of Health and Human Services Office of Inspector General (OIG) issued a Special Fraud Alert (Alert) concerning the fraud and abuse risks associated with healthcare practitioners entering into arrangements with telemedicine companies. The Alert follows dozens of civil and criminal investigations into alleged fraud schemes involving companies that claimed to provide telehealth, telemedicine or telemarketing services but allegedly engaged in kickbacks and substandard medical practices to generate medically unnecessary orders and prescriptions for items or services, resulting in submissions of fraudulent claims to Medicare, Medicaid and other federal healthcare programs.
The Alert also comes on the heels of a nationally coordinated US Department of Justice (DOJ) takedown involving more than $1 billion in allegedly fraudulent telemedicine schemes. The Alert identifies seven characteristics which could suggest a telemedicine arrangement presents potential risk for fraud and abuse. While the characteristics highlighted in the Alert are not representative of the legitimate and crucial telemedicine services offered by most healthcare providers, the Alert and the government’s sustained focus on potential telemedicine-related fraud cases provide an important opportunity for healthcare providers to evaluate their telemedicine offerings and arrangements and strengthen their telemedicine compliance activities.
In addition to the Alert, recent enforcement actions focused on telemedicine providers who prescribe controlled substances and corresponding congressional scrutiny of telemedicine providers indicates additional caution is warranted with respect to arrangements involving the prescription of controlled substances via telemedicine.
OIG released an Alert providing information and additional guidance to help health care practitioners identify potentially suspect arrangements with companies that purport to provide telehealth, telemedicine, or telemarketing services, some of which may be new to the market and created during the COVID-19 pandemic (collectively, Telemedicine Companies). The Alert appears to be directed towards physicians who may think that they are dealing with legitimate telemedicine companies, but who may need to verify that such companies have business models that are compliant with industry standards and regulations.
In addition to the Alert, there has been an increasing amount of enforcement action focused on Telemedicine Companies following the explosive growth in telemedicine services during the COVID-19 pandemic. During the pandemic, federal and state emergency actions vastly expanded telemedicine access, coverage and payment, which created additional incentives for health care providers to utilize telemedicine to provide care to their patients. Many health care providers have partnered with established and start-up Telemedicine Companies to facilitate the provision of care to their patients via telemedicine.
BACKGROUND
In recent years, the government has increasingly focused on alleged healthcare fraud schemes involving telemedicine services. For example, on September 30, 2020, the DOJ announced its largest fraud and opioid enforcement action in its history (Operation Rubber Stamp), which involved more than $6 billion in alleged fraud losses. Prior to this blockbuster enforcement action, the DOJ announced various coordinated telemedicine enforcement actions, including 2019’s Operation Brace Yourself and Operation Double Helix. In 2021, the DOJ continued this trend with the telemedicine component of the 2021 National Health Care Fraud Enforcement Action, which primarily focused on payment.
On July 20, 2022, the DOJ continued where it left off when it announced criminal charges against 36 defendants in 13 federal districts across the United States for more than $1.2 billion in alleged fraudulent telemedicine, cardiovascular and cancer genetic testing and durable medical equipment (DME) schemes. The federal investigations primarily targeted alleged schemes involving the payment of illegal kickbacks and bribes by laboratory owners and operators in exchange for the referral of patients by medical professionals working with fraudulent telemedicine and digital medical technology companies. In total, telemedicine schemes accounted for more than $1 billion of the total alleged intended losses associated with the enforcement action. In connection with the takedown, the DOJ issued a graphic summarizing the telemedicine enforcement actions and providing an example of telemedicine fraud schemes and also updated its summary of telemedicine enforcement cases.
Coinciding with the DOJ’s most recent enforcement actions—and following dozens of OIG and DOJ investigations into civil, criminal and administrative fraud schemes involving Telemedicine Companies—the OIG issued the Alert. Simultaneous with the release of the Alert, the OIG updated its Telehealth Resource Page, which provides compliance and enforcement resources.
ALLEGED FRAUD SCHEMES
The Alert focuses on alleged telemedicine fraud schemes that the OIG and DOJ have investigated in recent years under the Anti-Kickback Statute (AKS), the False Claims Act (FCA) and other federal statutes and regulations. These schemes vary in design and operation and have involved a wide range of individuals and types of entities. However, a common element in the alleged schemes is the use of kickbacks by Telemedicine Companies to recruit and reward practitioners. According to the Alert, these schemes typically involve Telemedicine Companies contracting with providers or provider groups to order or prescribe medically unnecessary items and services for individuals who are solicited and recruited by Telemedicine Companies or their marketing firm. Frequently, the alleged schemes involve Telemedicine Companies paying practitioners in exchange for ordering or prescribing items or services for patients the practitioner never examined or meaningfully assessed to determine the medical necessity of items or services ordered or prescribed. The OIG states that these payments may be described as a payment per review, audit, consult or assessment of medical charts, although there are legitimate Telemedicine Companies that rely on this type of compensation methodology. The Telemedicine Companies may tell practitioners they do not need to contact the patient or even review medical records and may direct practitioners to order or prescribe a preselected item or service, limiting the practitioner’s independent professional medical judgment regardless of the medical necessity or clinical appropriateness of said item or service. In many cases, according to the OIG, the Telemedicine Company sells the practitioner’s order or prescription generated to other individuals or entities that then fraudulently bill for the unnecessary items and services. The Alert warns that these alleged schemes implicate multiple federal laws, including the AKS. Practitioner arrangements with Telemedicine Companies may also lead to criminal, civil or administrative liability under other federal laws including the OIG’s exclusion authority related to kickbacks, the Civil Monetary Penalties Law provision for kickbacks, the criminal healthcare fraud statutes and the FCA. Practitioners may be personally liable for these types of arrangements if they are involved in ordering or prescribing medically unnecessary items or services.
OIG’S SUSPECT CHARACTERISTICS
Based on the OIG and DOJ’s telemedicine enforcement experience, the Alert identifies a non-exhaustive list of seven “suspect characteristics” related to practitioner arrangements with Telemedicine Companies which, taken together or separately, could suggest an arrangement that presents a heightened risk of fraud and abuse:
ANALYSIS
Compensation arrangements that involve per-order or per-item prescribed payment methodologies may not be able to receive protection under statutory or regulatory exceptions to the AKS, insofar as such compensation methods consider the volume or value of items ordered or referred that may be reimbursed by federal healthcare programs. The OIG has highlighted its concerns in the Alert that volume-based fees may corrupt medical decision-making, drive inappropriate utilization of healthcare services and result in patient harm. Accordingly, arrangements that incorporate these compensation methodologies require a more specific facts-and-circumstances analysis.
Many of the fraud cases highlighted by the OIG and DOJ involve fraudulent billing, in addition to alleged violations of the AKS. In particular, the Alert emphasizes that healthcare providers should pay extra attention to whether a Telemedicine Company is billing payors for the items and services it is furnishing to patients and which payors the Telemedicine Company is accepting. For example, some of the settlements highlighted by the OIG in the Alert involved Telemedicine Companies affiliated with telemarketing providers who directly call Medicare beneficiaries to generate patient “referrals.” Once the healthcare provider reviewed the medical record and (falsely) certified the medical necessity of the services for the patient, the Telemedicine Company submitted a bill for the services to federal healthcare programs. Healthcare providers should be sure that arrangements with Telemedicine Companies clearly specify which entity is responsible for billing federal healthcare programs and other payors for services furnished under the arrangement.
In addition to the suspect characteristics described by the OIG in the Alert, there has also been very recent congressional interest in potential fraud and abuse with respect to telemedicine arrangements. On June 6, 2022, Representative Gerald E. Connolly, chairman of the House Subcommittee on Government Operations (Subcommittee), sent a letter (Connolly Letter) to the US Drug Enforcement Agency (DEA) administrator highlighting concerns that online mental health providers were abusing the regulatory exception that allows for remote prescription of controlled substances with an in-person medical exam. The Connolly Letter cites concerns about aggressive marketing schemes and advertising practices that allegedly may influence clinical staff to prescribe drugs without sufficient oversight. It also cites concerns with how federal programs and agencies may be monitoring orders and shipments of prescribed drugs and requests information from the DEA for consideration by the Subcommittee. Accordingly, additional congressional interest and follow-up in this area is possible.
KEY TAKEAWAYS
As the Alert emphasizes, it is not the OIG’s intention to discourage legitimate telemedicine arrangements. Rather, healthcare providers and practitioners should use heightened scrutiny, exercise caution and consider the seven suspect criteria noted in the Alert prior to entering into arrangements with Telemedicine Companies.
Accordingly, Telemedicine Companies and healthcare providers should:
The Alert demonstrates that proposed arrangements with Telemedicine Companies continue to require careful review to ensure compliance with applicable fraud and abuse laws and billing requirements.
It is also noteworthy that the Connolly Letter emphasizes the DEA’s authority under the Controlled Substances Act to establish a telemedicine special registration. Such telemedicine special registration would allow the DEA to specify parameters for what is permissible in the context of controlled substances via telemedicine without a prior in-person medical evaluation. While the DEA has not yet issued regulations establishing the telemedicine special registration, recent increases in enforcement activity may prompt the DEA to take action in this area. Accordingly, healthcare providers and Telemedicine Companies should continue to monitor DEA regulatory activities, as well.

ARTICLE / CLIENT ALERT
July 28, 2022
Read time: 5 min
On July 13, 2022, the Securities and Exchange Commission (the “SEC”) proposed amendments (the “Proposed Amendments”) to the shareholder proposal rule, otherwise known as Rule 14a-8.
Rule 14a-8 provides shareholders with the right to submit proposals for inclusion in a company’s proxy statement in connection with its annual meeting. A proposal submitted pursuant to Rule 14a-8 must be added to a company’s annual meeting agenda and included in its proxy statement, unless the proposal runs afoul of certain procedural or substantive requirements, as outlined under Rule 14a-8, in which case a company may exclude the shareholder proposal.
There are currently 13 substantive bases upon which companies may rely in excluding shareholder proposals. The Proposed Amendments revise three of these bases in an effort to “provide a clearer framework […] which market participants have sought.”
The three exclusionary bases and their Proposed Amendments are as follows:
1. Substantial Implementation: Rule 14a-8(i)(10) currently allows a company to exclude shareholder proposals asking the company to take an action that it has already substantially implemented.
2. Duplication: Rule 14a-8(i)(11) currently allows a company to exclude a shareholder proposal that “substantially duplicates” a proposal previously submitted to the company by another proponent that will be included in the company’s proxy materials for the same meeting.
3. Resubmission: Rule 14a-8(i)(12) currently allows a company to exclude a shareholder proposal addressing substantially the same subject matter as a previous proposal that was included in a company’s proxy statement within the preceding five calendar years (and assuming the proposal was voted on at least once in the prior three years and did not receive sufficient shareholder support[1]).
The SEC has stated that the Proposed Amendments are designed to provide “greater certainty and transparency” to shareholders and companies evaluating shareholder proposals and to “facilitate shareholder suffrage and communication between shareholders and the companies they own,” with a goal of putting forward more value-enhancing policy changes. In November 2021 the SEC also released guidance favorable to shareholders submitting Rule 14a-8 proposals, particularly those related to ESG matters (discussed here).
The Proposed Amendments represent a positive development for shareholders and should result in an overall increase in the percentage of shareholder proposals that shareholders will have an opportunity to vote on.
The comment period for the Proposed Amendments will close 30 days after publication in the Federal Register or Sept. 12, 2022, whichever is later.
Authored by Eleazer Klein, Adriana Schwartz, Abraham Schwartz and Vera Lee.
[1] The resubmission support thresholds were the subject of a previous Alert we authored and can be found here.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2022 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

ARTICLE / REPORT
July 2022
Read time: 2 min
We are delighted to share our next issue of the Bulletin Concurrence which follows developments through the months of April to June.
To read the full Bulletin in French, please click here.

ARTICLE / CLIENT ALERT
July 25, 2022
Read time: 7 min
When an organization experiences a ransomware attack, it must address significant—and sometimes competing—challenges under pressing deadlines. These challenges include the following: evicting the threat actor from the network environment; restoring affected systems; recovering encrypted data, where viable backups exist; conducting a forensic investigation to determine the intrusion vector and scope of compromise; and communicating with an array of stakeholders (such as customers, vendors, insurers, employees, law enforcement, regulators and the media).
Organizations also must evaluate notice obligations amid a patchwork of laws and regulations, as well as under the contracts they hold. There are sector-specific reporting requirements for regulated industries.[1] Every US state has its own data breach notification law. And public companies must take “all required actions” to inform investors about material cybersecurity risks and incidents.[2]
When it comes to making a ransom payment, the primary legal hurdle to clear has been the US Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctions regime.[3] That hurdle is now getting higher. A burgeoning body of state law is restricting how organizations—specifically, public sector entities—can respond to ransomware incidents and pay demands.
On July 1, 2022, Florida joined North Carolina to become the second US state to prohibit state and local government agencies from complying with or paying ransomware demands. Florida’s law also imposes hair-trigger notification requirements on those agencies. While at first blush the impact of the Florida and North Carolina laws appears limited to ransomware attacks on state and local government entities, these new laws create a number of novel questions with potentially broader application.
Florida and North Carolina may not be the end of the line in this area of law. There also are ransomware-related bills currently pending in Arizona, New York, Pennsylvania and Texas,[4] as well as federal bills introduced in Congress.[5] These statehouse developments could soon result in a balkanized compliance framework akin to data breach notification laws.
This article provides an overview of the new ransomware laws and previews some of the pending state and federal legislation. The article also explores implications the ransomware prohibitions may have beyond the public sector agencies to which they facially apply. At bottom, responding to ransomware attacks has always been a high-stakes, complex undertaking, and with these new laws, it has now gotten even more challenging for organizational victims.
WHAT FLORIDA’S NEW LAW REQUIRES
Florida CS/HB 7055 amends the State Cybersecurity Act to impose new cybersecurity requirements on Florida state, county and local government agencies, including forthcoming guidelines and processes for cataloging and managing IT systems, conducting risk assessments, cybersecurity standards, data recovery, incident response, cybersecurity training and reporting cybersecurity and ransomware incidents.[6]
With respect to a ransomware incident, which is defined broadly under the Act:[7]
The Act also requires guidelines, processes and standards be issued and adopted over the next two years, including the following:
These forthcoming materials are sure to create additional obligations on Florida state and local government agencies, as well as have cascading effects on other entities.
OTHER LEGISLATION GOVERNING RANSOMWARE RESPONSE
Florida’s law follows on the heels of North Carolina, the first state to enact a law prohibiting state agencies and local government entities from negotiating with ransomware actors or paying a ransomware demand. North Carolina’s notification provision is not as stringent as the Florida law, as it simply requires an agency or entity to “consult” the North Carolina Department of Information Technology when there is a ransomware incident.[16]
Similar and more expansive statutes are being considered across the US, including Arizona, New York, Pennsylvania and Texas.
At the federal level, there have been a number of bills introduced in this Congress. The proposed Ransomware and Financial Stability Act would prohibit US financial institutions from making a ransom payment greater than $100,000 unless given explicit authorization by a federal law enforcement agency. And the proposed Ransom Disclosure Act would require public and private entities to report any ransom payments within 48 hours to the US Department of Homeland Security (DHS) through a DHS-created portal.
TAKEAWAYS FROM THE NEW LAWS
For public sector victims in Florida and North Carolina, the options for responding to ransomware incidents just became much more limited. Recognizing the public policy rationale against negotiating with and paying criminal actors, as a practical matter, the new laws place government agencies in a very difficult position where critical data is encrypted, backups are not accessible, and payment is the only viable path to restoration and recovery. Yes, over the long term, enhanced cybersecurity will reduce the likelihood of such a predicament, but it will not resolve near-term needs. More broadly, where a ransomware incident affects data belonging to multiple states’ data being held by a single entity, will the new laws restrict the ability to negotiate and/or pay a demand? The forthcoming Florida guidelines, processes and standards likely will create additional compliance questions for government agencies, as well as the entities that access data and systems belonging to those agencies. And if New York’s pending bill is any indication, the reaches of this new wave of legislation may extend far beyond organizations with access to government data. Thus, businesses would be wise to monitor developments in these states and others that take up ransomware-related legislation and seek legal advice as questions inevitably arise.
John Ying, a Summer Associate in the Atlanta office, also contributed to this article.

ARTICLE
Jul 22, 2022
Read time: 4 min
The Court of Appeals of Texas (Fourth District) upheld a trial court’s order denying a motion to dismiss a breach of confidentiality agreement claim pursuant to the Texas Citizens Participation Act (TCPA), which is designed to protect people from strategic lawsuits against public participation (SLAPP). Harper v. Crédito Real Bus. Cap., Case No. 21-0212 (Tex. App. July 20, 2022) (Martinez, Chapa, Watkins, JJ.)
Crédito Real Business Capital (CRBC) leases equipment and provides financing services to companies in the construction industry. CRBC provides its services through two limited liability companies: CR-FED and CR-FED Leasing. Earl Harper previously worked for CRBC as executive vice president and was required to sign a confidentiality agreement with CR-FED stipulating that he would not share its confidential information with third parties.
CRBC advanced money and leased equipment to Ontrack Site Services, a site grading contractor and customer with whom Harper worked. As part of his employment, Harper was provided with confidential information regarding CRBC’s plans and projections for its relationship with Ontrack, including CRBC’s willingness to extend additional financing or leasing services to the contractor. Harper allegedly used this information to help Ontrack negotiate better lease rates and financing terms to CRBC’s detriment. CRBC terminated Harper’s employment. Harper subsequently joined a new company and advised Ontrack to obtain financing from that company instead of CRBC.
CRBC sued Harper for breach of fiduciary duty and breach of contract for misappropriating CRBC’s trade secrets and breaching the confidentiality agreement. Harper filed a motion to dismiss the breach of contract claim pursuant to the TCPA, under which a party can file a motion to dismiss a lawsuit if it “is based on or is in response to a party’s exercise of the right of free speech, right to petition, or right of association.” The trial court denied the motion. Harper appealed, contending the following:
A motion to dismiss pursuant to the TCPA is evaluated under a three-step burden shifting framework:
The Texas Court of Appeals first addressed whether the trial court was permitted to consider CRBC’s amended petition when it ruled on the motion to dismiss. CRBC’s amended petition merely clarified that “CRBC” was the assumed name for both CR-FED and CR-FED Leasing, rather than just CR-FED. Because the amended petition was filed well before the hearing date and did not include any element of surprise, the Court concluded that the trial court properly considered the amended petition when making its decision.
The Texas Court of Appeals next assumed that the TCPA applied and considered whether CRBC had established a prima facie case for its breach of contract claim. In support of its claim, CRBC had produced a copy of the confidentiality agreement and affidavits from CRBC managers attesting that CRBC had shared confidential pricing and financing information with Harper. The affidavits further claimed that Harper told Ontrack that he would help it secure additional financing from CRBC, drafted an email to CRBC on Ontrack’s behalf that induced CRBC to provide more funding, and informed Ontrack that it could get cheaper rates elsewhere. The Court concluded that CRBC had met its burden of showing that Harper had breached the confidentiality agreement, even though the agreement was only between Harper and CR-FED. The Court thus affirmed the trial court’s order denying Harper’s motion to dismiss.